We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Intelligent Ultrasound Group Plc | LSE:MED | London | Ordinary Share | GB00BN791Q39 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 14.50 | 14.00 | 15.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMMED
RNS Number : 3017M
Medaphor Group PLC
07 January 2019
7 January 2019
MedaPhor Group plc
("MedaPhor" or the "Group" or the "Company")
Trading update
MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announces that Group turnover for the year to 31 December 2018, which was generated entirely by the Group's Simulation Division, is expected to grow by approximately 27% to between GBP5.3m and GBP5.4m (2017: GBP4.2m). The pre-exceptionals EBITDA loss for the year is expected to be around GBP3m (2017: Loss, GBP1.7m). This includes approximately GBP1.5m of primarily R&D expenses attributable to investment in the Group's Clinical Artificial Intelligence Division which was established with the acquisition of Intelligent Ultrasound Limited ("IUL") on 6 October 2017 (3 months to 31 December 2017, IUL overheads: GBP0.2m). Group management, PLC costs and share-based payment charges included in the adjusted loss are expected to be GBP0.9m (2017: GBP0.8m).
GBP4.86m net of costs was received in December from the placing and open offer (RNS: 40941, 26 November 2018) and cash at bank at 31 December 2018 was GBP5.5m (2017: GBP4.3m).
Enquiries:
Hot Features
Premium
MedaPhor Group plc www.medaphor.com
Stuart Gall, CEO Tel: +44 (0)29 2075 6534
Wilson Jennings, CFO
Cenkos Securities - Nominated Tel: +44 (0)20 7397 8900
Advisor and broker
Giles Balleny / Cameron MacRitchie
(Corporate Finance)
Michael Johnson / Julian Morse
(Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or medaphor@walbrookpr.com
Anna Dunphy / Paul McManus Mob: +44 (0)7876 741 001 / Mob: +44
(0)7980 541 893
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
TSTSSFSUMFUSESF
(END) Dow Jones Newswires
January 07, 2019 02:00 ET (07:00 GMT)
1 Year Intelligent Ultrasound Chart |
1 Month Intelligent Ultrasound Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
